Posts by: Patricia Inacio PhD

News

In a new study entitled “Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity” scientists at Cancer Research UK unveiled a new mechanism that allows neuroblastoma ... Read more

July 28, 2015July 28, 2015

New Clinical Trial for BRAFV600-Advanced Melanoma Currently Recruiting Patients

News

A new clinical trial, entitled “Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma” ... Read more

July 21, 2015July 21, 2015

Agenus Acquires Antibodies To Develop New Anti-Cancer Immunotherapies

News

Agenus Inc., a leading company in the filed of immunotherapies, has just announced the acquisition of the rights for antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), that were held by Italian ... Read more

July 13, 2015July 13, 2015

Potential New Immunotherapy For Melanoma

News

In a new study entitled “T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model” researcher’s at ... Read more

July 7, 2015July 7, 2015

Eliminating Circulating Tumor Cells With Extracorporeal-PhotoTherapy

News

In a new study entitled “Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells” a team of researchers tested whether they could eliminate circulating tumor cells (key agents in promoting cancer metastasis) from ... Read more

July 2, 2015July 2, 2015

SillaJen Shows Multiple Intravenous Doses of Oncolytic Immunotherapy Safe in Cancer Patients

News

SillaJen, Inc., a biotechnology company focused on developing oncolytic immunotherapies, announced the results of a Phase Ib trial for refractory, metastatic colorectal cancer patients treated with their leading treatment, Pexa-Vec. ... Read more

June 26, 2015June 26, 2015

Leukemia Patients In Remission After Receiving New Epigenetic Therapy

News

In a new study entitled “Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia” researchers at the University of Virginia Cancer Center developed a new treatment strategy to fight ... Read more

June 23, 2015September 9, 2015

CAR-Modified T-Cell Therapy As Potential New Treatment For Non-Hodgkin Lymphomas

News

Results of a new study entitled “Phase II trial of chimeric antigen receptor modified T cells directed against CD19 in relapsed/refractory diffuse large B cell, follicular, and mantle cell lymphomas” ... Read more

June 22, 2015June 22, 2015

Enhancing Anti-Tumoral Immunity by Inhibiting Specific Enzyme

News

In a new study entitled “Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy” researchers showed that inhibiting an enzyme – dipeptidylpeptidase 4 (DPP4) – responsible ... Read more

June 17, 2015June 17, 2015

Adoptive Cell ImmunoTherapy (ACT) – Advancing Personalised Cancer Treatment

News

In a special issue of the journal Immunotherapy a group of experts discuss the latest developments in adoptive cell immunotherapy and new strategies to further enhance its use as a ... Read more